Suggested remit - To appraise the clinical and cost effectiveness of entrectinib within its proposed marketing authorisation for treating NTRK fusion-positive advanced solid tumours
Status In progress
Process STA 2018
ID number 1512

Provisional Schedule

Final appraisal document 25 June 2020 - 09 July 2020
Expected publication 12 August 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors Roche (entrectinib)
  Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups GIST UK
  Roy Castle Lung Cancer Foundation
  Sarcoma UK


General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Janssen-Cilag Ltd
  Servier Laboratories Ltd
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
23 December 2019 This appraisal was discussed by the technology appraisal committee on 20 November 2019. The committee’s decision will be released to consultees and commentators once positive CHMP opinion has been granted.
20 November 2019 Committee meeting
08 March 2019 Invitation to participate
14 November 2018 - 12 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 October 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance